Suggestions

CTKB · NASDAQ

CYTEK BIOSCIENCES INC

Private beta

Sector unavailable · Industry unavailable

$4.61

+1.77%

Close on Sep 11, 2026

Insufficient Data

Updated 12/18/2023

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Investment Report Card

CYTEK BIOSCIENCES INC

Sector unavailable · Data confidence limited

No Pro Investor Score today

Risk Intelligence is unavailable

Risk Intelligence

Core Model

Not Available

Insufficient Data

How strong and defensively sound is the company?

This reading is not available for this company yet.

Long-Term Potential

Research Model

Not Available

Insufficient Data

Does the business have the characteristics needed to create value over many years?

This reading is not available for this company yet.

Fundamental Momentum

Research Model

Not Available

Insufficient Data

Is the underlying business getting stronger or weaker?

This reading is not available for this company yet.

Ownership Intelligence

Supplemental Intelligence

Not Available

Positive disclosed activity

What are important owners actually doing?

This reading is not available for this company yet.

Valuation Intelligence

Research Model
B−

73 / 100

Very Attractive

Is today's price reasonable?

Above average on this measure — and valuation is researched separately from the Suggested Investment Score.

Capital Returns Intelligence

Research Model
F

16 / 100

Limited Capital Returns

How effectively does the company reward shareholders?

Weaker than most covered companies on this measure — and capital returns are researched separately from the Suggested Investment Score.

Why it stands out

  • More disclosed holders are new or increasing than reducing or exiting.
  • Attractive valuation: the stock reads 73 out of 100 on Valuation Intelligence (Very Attractive) relative to its own history and comparable companies.

What holds it back

No weakening evidence is recorded in today's readings.

Long-term view

Long-Term Potential is not available for this company, so no long-term reading is shown.

Ownership view

No disclosed ownership reading is available at the required confidence, so ownership is left blank rather than estimated.

Valuation view

CYTEK BIOSCIENCES INC reads 73 out of 100 on Valuation Intelligence, recorded as Very Attractive. The stock currently trades below most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

Capital returns view

CYTEK BIOSCIENCES INC reads 16 out of 100 on Capital Returns Intelligence (Limited Capital Returns), reflecting a share count rising about 32.4% a year. Direct capital returns are limited because the company continues reinvesting most of its cash. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

What changed

No meaningful recorded changes in the stored history.

Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.

Compare CTKB with other companies

Appears in

Rule-based membership

Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.

60-Second Brief

Too few stored readings exist for this company to summarise honestly.

Composite discovery model

Pro Investor Score

Pro Investor Score™

Not currently in the Suggested Investment ranking

Risk Intelligence is unavailable. A composite score is only published when every required input is available for this company. Nothing is estimated to fill a gap, and exclusion from the ranking is not a sell instruction.

COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Ranking updated September 12, 2026

Researched separately

Valuation Intelligence 73 · Very Attractive

RESEARCH MODEL

Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.

Researched separately

Capital Returns Intelligence 16 · Limited Capital Returns

RESEARCH MODEL

Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.

Why this company scores the way it does

This company does not currently hold a stored Pro Investor Score, so no contribution breakdown can be shown.

Pro Investor Intelligence™

Reported by insiders, large shareholders and professional funds. Shown beside our research, never blended into it.

Loading professional-investor activity…

Stored snapshots only

What changed

Research-score history available since September 2026.

Stored research history does not yet cover a full 30 days comparison for this company.

A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

Fifth research lens · outside the score

Valuation Intelligence

Valuation Intelligence

Is today's price reasonable?

Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.

73/ 100

Very Attractive

RESEARCH MODEL
Good coverage

Compared with its history

72

Very Attractive

Is this company expensive or inexpensive compared with its own history?

Compared with peers

52

Reasonable

How expensive is this stock compared with similar companies?

Earnings & cash flow

Not Available

How much financial output does an investor receive relative to the price paid?

No positive earnings or cash-flow yield is available, so this lens is not scored.

Growth-adjusted

100

Very Attractive

Does the company's growth help justify the valuation investors are paying?

CYTEK BIOSCIENCES INC reads 73 out of 100 on Valuation Intelligence, recorded as Very Attractive. The stock currently trades below most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.

Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026

Valuation history

Stored readings only. The dashed line is this company's own median for the selected measure.

Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.

Current EV/Sales 2.6x · own median 3.5x · peer median 2.8x

Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.

Sixth research lens · outside the score

Capital Returns Intelligence

Capital Returns Intelligence

How effectively does the company reward shareholders?

Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.

16/ 100

Limited Capital Returns

RESEARCH MODEL
Good coverage

Dividend Quality

Not Applicable — No Dividend

Dividend reliability

This company currently retains rather than distributes cash through dividends. Capital Returns Intelligence therefore places more emphasis on its other measurable shareholder-return behaviors according to the frozen V1 methodology.

Buyback Effectiveness

30

Limited Capital Returns

Do buybacks actually reduce shares?

The company spends on share repurchases, but much of that activity offsets share issuance rather than materially reducing the share count.

Dilution Control

5

Limited Capital Returns

Is your ownership share protected?

Capital Return Sustainability

Not Available

Can the cash flow support it?

No usable cash-flow or earnings measure is stored, so coverage cannot be confirmed.

Shareholder Yield

5

Limited Capital Returns

Cash returned versus company value

CYTEK BIOSCIENCES INC reads 16 out of 100 on Capital Returns Intelligence (Limited Capital Returns), reflecting a share count rising about 32.4% a year. Direct capital returns are limited because the company continues reinvesting most of its cash.

This company currently retains rather than distributes cash through dividends. Capital Returns Intelligence therefore places more emphasis on its other measurable shareholder-return behaviors according to the frozen V1 methodology.

This company spent cash repurchasing stock, but the share count did not fall meaningfully because it also issued shares. Repurchase spending alone did not increase existing shareholders' ownership.

How returned cash was used

Dividends $0.00 · net repurchases $24.40M · total returned $24.40M

Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026

Capital returns history

Stored readings only. History builds forward from activation rather than being reconstructed.

Only one stored reading exists for this measure so far, so there is nothing to chart yet.

Why higher yield isn't always better

A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.

Why buybacks can be misleading

Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.

What these terms mean
Dividend Yield
The annual dividend relative to the current share price.
Payout Ratio
The share of company earnings used to pay dividends.
Free Cash Flow Payout
How much of the company's available cash is being used for dividends.
Share Repurchases
When a company buys back its own stock.
Dilution
When the number of shares increases, reducing each existing share's percentage ownership of the company.
Shareholder Yield
A combined view of dividends and net share repurchases relative to the company's market value.

Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Pro Investor Score.

Stored daily snapshots only

Ranking history

Stored Suggested Investment ranking history
TodayNot rankedNo stored score
30 days agoNot rankedNo stored score
90 days agoNot rankedNo stored score
First suggestedNot yet suggested
Highest rankNot ranked

In the company’s own words

What this company does

We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells ("Full Spectrum Profiling" or "FSP" technology). Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.

Biological systems are highly complex, and scientists are challenged by the multitude of questions that remain unanswered. Analysis at the single-cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological question can have profound implications for drug development and health care decisions. It is essential to correlate information derived from multiple cell analysis approaches and to translate what is known at the gene level to the actual cell function. As a result, there is growing demand for deep content through high dimensional cell analysis and for solutions that can provide a complete picture of cellular biological processes and interactions. To achieve this, scientists need to phenotype and isolate rare events or unique populations down to the single-cell level through highly resolvable multi-dimensional cell analysis. While flow cytometry is a widely used tool for single cell analysis, conventional flow cytometry, mass cytometry and early approaches to spectral flow cytometry technologies have historically been challenged due to limited dimensionality, sub-optimal resolution, low throughput, high cost for performance and/or significant technical expertise required to operate systems.

Our patented FSP technology optimizes sensitivity and accuracy through its unique optical and electronic designs that utilize an innovative method of light detection and distribution to a specifically selected number and type of detectors. This patented optics design enables researchers to effectively collect the full range of light emissions in an extremely compact space, resulting in higher resolution and enabling the development of highly complex assays with 50 different colors (individual fluorochromes), supporting 50 biomarkers within just a single tube.

Our FSP cell analyzers, the Cytek Aurora , Northern Lights , and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies by providing a higher level of multiplexing with exquisite sensitivity, more flexibility and increased efficiency, all at a lower cost for performance. Additionally, our Cytek Aurora cell sorter ("Aurora CS system") leverages our FSP technology to further broaden our potential applications across cell analysis by enabling the same number of parameters with the same sensitivity as the Cytek Aurora and Cytek Aurora Evo cell analyzer systems. Each system is supported by our highly intuitive, proprietary embedded SpectroFlo software, our reagents, and our service offerings to provide a comprehensive, end-to-end platform of solutions for our customers.

Quoted from the business section of this company’s 10-K filed February 26, 2026. Read the filing

Four distinct intelligence areas

The IA view

Risk Intelligence

Production core

31

Exit Review

No prior period to compare

Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.

As of Sep 11, 2026

Long-Term Potential

Research model

Insufficient Data

No prior period to compare

Durable business economics and reinvestment characteristics. Independent external validation is pending.

Fundamental Momentum

Research model

Insufficient Data

No prior period to compare

Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.

Elite Investor Activity

Supplemental

Insufficient Data

No prior period to compare

No tracked manager filings mapped to this company.

Intelligence history

Not enough stored history to chart CTKB yet. A company needs at least two published research or ownership periods before a trend can be shown.

Share price

CTKB price history

Closing prices adjusted for splits and dividends, through Sep 11, 2026. Past prices do not indicate future results.

6M change
+15.0%
1Y change
+16.4%
3Y change
-34.1%
5Y change
-82.8%
Max change
-75.4%

Last stored close $4.61 · +16.4% over the selected range · 64 sessions shown

Balanced evidence

Why IA likes it

  • More disclosed holders are new or increasing than reducing or exiting.

Risk and uncertainty

What IA doesn’t like

  • No specific negative evidence is available. This is not evidence of low risk.

What would change our view

  • Business Quality falling below the frozen qualification threshold.
  • Price Risk moving to a less favorable category.
  • A sustained reversal in the Fundamental Momentum research evidence.
  • New material public ownership disclosures.

Public filings · descriptive only

Elite Investor Activity

Reporting holders

8

New holders

7

Increasing

1

Reducing

0

Exiting

0

Coverage

Excellent

Positive disclosed activity · Report period 2023-09-30 · Public 12/18/2023

ManagerChangePortfolio weightRankDisclosed

Insufficient high-confidence manager coverage.

Objective stored changes

What changed

No qualifying changes are recorded for this company in the stored research and filing history.

Ownership timeline

No high-confidence public ownership events are available.

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.